EP4210837A1 - Nouvelle émulsion mimant la peau - Google Patents
Nouvelle émulsion mimant la peauInfo
- Publication number
- EP4210837A1 EP4210837A1 EP21785937.0A EP21785937A EP4210837A1 EP 4210837 A1 EP4210837 A1 EP 4210837A1 EP 21785937 A EP21785937 A EP 21785937A EP 4210837 A1 EP4210837 A1 EP 4210837A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- skin
- composition
- dermo
- chosen
- active ingredient
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000839 emulsion Substances 0.000 title abstract description 25
- 239000000203 mixture Substances 0.000 claims abstract description 227
- 239000002537 cosmetic Substances 0.000 claims abstract description 90
- 150000002632 lipids Chemical class 0.000 claims description 59
- 239000004480 active ingredient Substances 0.000 claims description 48
- 238000000034 method Methods 0.000 claims description 44
- 241000894006 Bacteria Species 0.000 claims description 30
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 24
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N squalane Chemical compound CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 claims description 19
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 18
- 239000000284 extract Substances 0.000 claims description 18
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 claims description 16
- 150000002191 fatty alcohols Chemical class 0.000 claims description 15
- 230000001580 bacterial effect Effects 0.000 claims description 14
- 150000001875 compounds Chemical class 0.000 claims description 14
- 208000003251 Pruritus Diseases 0.000 claims description 13
- 150000004676 glycans Chemical class 0.000 claims description 13
- 229920001282 polysaccharide Polymers 0.000 claims description 13
- 239000005017 polysaccharide Substances 0.000 claims description 13
- 201000004624 Dermatitis Diseases 0.000 claims description 12
- 150000001413 amino acids Chemical class 0.000 claims description 12
- 229940043375 1,5-pentanediol Drugs 0.000 claims description 10
- CCOQPGVQAWPUPE-UHFFFAOYSA-N 4-tert-butylcyclohexan-1-ol Chemical group CC(C)(C)C1CCC(O)CC1 CCOQPGVQAWPUPE-UHFFFAOYSA-N 0.000 claims description 10
- WCVRQHFDJLLWFE-UHFFFAOYSA-N pentane-1,2-diol Chemical compound CCCC(O)CO WCVRQHFDJLLWFE-UHFFFAOYSA-N 0.000 claims description 10
- 210000004761 scalp Anatomy 0.000 claims description 10
- 241001303601 Rosacea Species 0.000 claims description 9
- 230000002757 inflammatory effect Effects 0.000 claims description 9
- 201000004700 rosacea Diseases 0.000 claims description 9
- 208000017520 skin disease Diseases 0.000 claims description 9
- 239000012178 vegetable wax Substances 0.000 claims description 9
- 241001135755 Betaproteobacteria Species 0.000 claims description 8
- 241000588656 Neisseriaceae Species 0.000 claims description 8
- 125000004432 carbon atom Chemical group C* 0.000 claims description 8
- 229940081733 cetearyl alcohol Drugs 0.000 claims description 8
- JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 claims description 8
- 229940032094 squalane Drugs 0.000 claims description 8
- 229930003231 vitamin Natural products 0.000 claims description 8
- 239000011782 vitamin Substances 0.000 claims description 8
- 235000013343 vitamin Nutrition 0.000 claims description 8
- 229940088594 vitamin Drugs 0.000 claims description 8
- 229940061720 alpha hydroxy acid Drugs 0.000 claims description 7
- 150000001280 alpha hydroxy acids Chemical class 0.000 claims description 7
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 claims description 7
- 230000002209 hydrophobic effect Effects 0.000 claims description 7
- LWGJTAZLEJHCPA-UHFFFAOYSA-N n-(2-chloroethyl)-n-nitrosomorpholine-4-carboxamide Chemical compound ClCCN(N=O)C(=O)N1CCOCC1 LWGJTAZLEJHCPA-UHFFFAOYSA-N 0.000 claims description 7
- 229920005862 polyol Polymers 0.000 claims description 7
- 150000003077 polyols Chemical class 0.000 claims description 7
- 229920006395 saturated elastomer Polymers 0.000 claims description 7
- 230000001225 therapeutic effect Effects 0.000 claims description 7
- 235000013311 vegetables Nutrition 0.000 claims description 7
- 150000003722 vitamin derivatives Chemical class 0.000 claims description 7
- SRBFZHDQGSBBOR-IOVATXLUSA-N D-xylopyranose Chemical compound O[C@@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-IOVATXLUSA-N 0.000 claims description 6
- 241000192142 Proteobacteria Species 0.000 claims description 6
- 201000004681 Psoriasis Diseases 0.000 claims description 6
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 claims description 6
- 208000010668 atopic eczema Diseases 0.000 claims description 6
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 claims description 6
- NOPFSRXAKWQILS-UHFFFAOYSA-N docosan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCCCCCO NOPFSRXAKWQILS-UHFFFAOYSA-N 0.000 claims description 6
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims description 6
- 230000001575 pathological effect Effects 0.000 claims description 6
- HLZKNKRTKFSKGZ-UHFFFAOYSA-N tetradecan-1-ol Chemical compound CCCCCCCCCCCCCCO HLZKNKRTKFSKGZ-UHFFFAOYSA-N 0.000 claims description 6
- OQILCOQZDHPEAZ-UHFFFAOYSA-N Palmitinsaeure-octylester Natural products CCCCCCCCCCCCCCCC(=O)OCCCCCCCC OQILCOQZDHPEAZ-UHFFFAOYSA-N 0.000 claims description 5
- GJQLBGWSDGMZKM-UHFFFAOYSA-N ethylhexyl palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC(CC)CCCCC GJQLBGWSDGMZKM-UHFFFAOYSA-N 0.000 claims description 5
- 230000036571 hydration Effects 0.000 claims description 5
- 238000006703 hydration reaction Methods 0.000 claims description 5
- 150000001261 hydroxy acids Chemical class 0.000 claims description 5
- 208000027866 inflammatory disease Diseases 0.000 claims description 5
- 229910052500 inorganic mineral Inorganic materials 0.000 claims description 5
- 239000011707 mineral Substances 0.000 claims description 5
- 239000000126 substance Substances 0.000 claims description 5
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 claims description 5
- 239000000230 xanthan gum Substances 0.000 claims description 5
- 229920001285 xanthan gum Polymers 0.000 claims description 5
- 235000010493 xanthan gum Nutrition 0.000 claims description 5
- 229940082509 xanthan gum Drugs 0.000 claims description 5
- 229960000541 cetyl alcohol Drugs 0.000 claims description 4
- 239000008172 hydrogenated vegetable oil Substances 0.000 claims description 4
- GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 claims description 4
- 239000007764 o/w emulsion Substances 0.000 claims description 4
- 239000000213 tara gum Substances 0.000 claims description 4
- 235000010491 tara gum Nutrition 0.000 claims description 4
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 claims description 3
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 claims description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 3
- 239000004373 Pullulan Substances 0.000 claims description 3
- 229920001218 Pullulan Polymers 0.000 claims description 3
- 241001558929 Sclerotium <basidiomycota> Species 0.000 claims description 3
- 229920002385 Sodium hyaluronate Polymers 0.000 claims description 3
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 claims description 3
- 150000001338 aliphatic hydrocarbons Chemical group 0.000 claims description 3
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 claims description 3
- PYMYPHUHKUWMLA-WDCZJNDASA-N arabinose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)C=O PYMYPHUHKUWMLA-WDCZJNDASA-N 0.000 claims description 3
- 150000001277 beta hydroxy acids Chemical class 0.000 claims description 3
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims description 3
- 229960000735 docosanol Drugs 0.000 claims description 3
- LQZZUXJYWNFBMV-UHFFFAOYSA-N dodecan-1-ol Chemical compound CCCCCCCCCCCCO LQZZUXJYWNFBMV-UHFFFAOYSA-N 0.000 claims description 3
- 239000008103 glucose Substances 0.000 claims description 3
- 229930182470 glycoside Natural products 0.000 claims description 3
- 125000003563 glycoside group Chemical group 0.000 claims description 3
- 150000002338 glycosides Chemical class 0.000 claims description 3
- 239000004310 lactic acid Substances 0.000 claims description 3
- 235000014655 lactic acid Nutrition 0.000 claims description 3
- 239000001630 malic acid Substances 0.000 claims description 3
- 235000011090 malic acid Nutrition 0.000 claims description 3
- 229940043348 myristyl alcohol Drugs 0.000 claims description 3
- 229930014626 natural product Natural products 0.000 claims description 3
- 239000000419 plant extract Substances 0.000 claims description 3
- 235000019423 pullulan Nutrition 0.000 claims description 3
- 229940010747 sodium hyaluronate Drugs 0.000 claims description 3
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 claims description 3
- 229940012831 stearyl alcohol Drugs 0.000 claims description 3
- 239000011975 tartaric acid Substances 0.000 claims description 3
- 235000002906 tartaric acid Nutrition 0.000 claims description 3
- 229920000084 Gum arabic Polymers 0.000 claims description 2
- 239000000205 acacia gum Substances 0.000 claims description 2
- 235000010489 acacia gum Nutrition 0.000 claims description 2
- 235000015165 citric acid Nutrition 0.000 claims description 2
- 239000013543 active substance Substances 0.000 claims 1
- 229920000591 gum Polymers 0.000 claims 1
- 230000008520 organization Effects 0.000 abstract description 32
- 239000004615 ingredient Substances 0.000 abstract description 13
- 210000003491 skin Anatomy 0.000 description 119
- 239000000047 product Substances 0.000 description 39
- 210000000434 stratum corneum Anatomy 0.000 description 39
- 239000001993 wax Substances 0.000 description 31
- 230000000694 effects Effects 0.000 description 20
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 16
- 108090000623 proteins and genes Proteins 0.000 description 15
- 210000002615 epidermis Anatomy 0.000 description 14
- 238000005259 measurement Methods 0.000 description 13
- 235000018102 proteins Nutrition 0.000 description 13
- 102000004169 proteins and genes Human genes 0.000 description 13
- 230000004888 barrier function Effects 0.000 description 12
- 230000035945 sensitivity Effects 0.000 description 12
- 235000001014 amino acid Nutrition 0.000 description 11
- 210000004027 cell Anatomy 0.000 description 11
- 238000012360 testing method Methods 0.000 description 11
- 208000035824 paresthesia Diseases 0.000 description 10
- 230000004044 response Effects 0.000 description 10
- 238000000235 small-angle X-ray scattering Methods 0.000 description 10
- 206010015150 Erythema Diseases 0.000 description 9
- 238000002441 X-ray diffraction Methods 0.000 description 9
- 239000006071 cream Substances 0.000 description 9
- 210000004207 dermis Anatomy 0.000 description 9
- 230000035807 sensation Effects 0.000 description 9
- 206010020751 Hypersensitivity Diseases 0.000 description 8
- 206010022998 Irritability Diseases 0.000 description 8
- 230000008859 change Effects 0.000 description 8
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 8
- 235000014113 dietary fatty acids Nutrition 0.000 description 8
- 239000000194 fatty acid Substances 0.000 description 8
- 229930195729 fatty acid Natural products 0.000 description 8
- 150000004665 fatty acids Chemical class 0.000 description 8
- 206010013082 Discomfort Diseases 0.000 description 7
- 230000007803 itching Effects 0.000 description 7
- 239000011159 matrix material Substances 0.000 description 7
- 230000037307 sensitive skin Effects 0.000 description 7
- 230000036572 transepidermal water loss Effects 0.000 description 7
- 150000003626 triacylglycerols Chemical class 0.000 description 7
- 238000004458 analytical method Methods 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 6
- 235000011187 glycerol Nutrition 0.000 description 6
- 150000002430 hydrocarbons Chemical group 0.000 description 6
- 210000002510 keratinocyte Anatomy 0.000 description 6
- 239000012071 phase Substances 0.000 description 6
- 239000003755 preservative agent Substances 0.000 description 6
- 230000009467 reduction Effects 0.000 description 6
- 206010006784 Burning sensation Diseases 0.000 description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 5
- 206010040830 Skin discomfort Diseases 0.000 description 5
- 239000002253 acid Substances 0.000 description 5
- 230000002996 emotional effect Effects 0.000 description 5
- 239000002609 medium Substances 0.000 description 5
- 244000005700 microbiome Species 0.000 description 5
- 230000001681 protective effect Effects 0.000 description 5
- 241000196324 Embryophyta Species 0.000 description 4
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 4
- 102000011782 Keratins Human genes 0.000 description 4
- 108010076876 Keratins Proteins 0.000 description 4
- 206010030113 Oedema Diseases 0.000 description 4
- 208000002193 Pain Diseases 0.000 description 4
- 206010039509 Scab Diseases 0.000 description 4
- 206010040844 Skin exfoliation Diseases 0.000 description 4
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 4
- 125000001931 aliphatic group Chemical group 0.000 description 4
- 239000012164 animal wax Substances 0.000 description 4
- 235000012000 cholesterol Nutrition 0.000 description 4
- 230000009089 cytolysis Effects 0.000 description 4
- 230000035618 desquamation Effects 0.000 description 4
- 239000000835 fiber Substances 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 239000003349 gelling agent Substances 0.000 description 4
- 239000007791 liquid phase Substances 0.000 description 4
- 235000010755 mineral Nutrition 0.000 description 4
- 230000003020 moisturizing effect Effects 0.000 description 4
- 239000003921 oil Substances 0.000 description 4
- 235000019198 oils Nutrition 0.000 description 4
- 150000003904 phospholipids Chemical class 0.000 description 4
- 230000008439 repair process Effects 0.000 description 4
- 239000000523 sample Substances 0.000 description 4
- 210000002374 sebum Anatomy 0.000 description 4
- 230000001953 sensory effect Effects 0.000 description 4
- 238000000926 separation method Methods 0.000 description 4
- YYGNTYWPHWGJRM-UHFFFAOYSA-N (6E,10E,14E,18E)-2,6,10,15,19,23-hexamethyltetracosa-2,6,10,14,18,22-hexaene Chemical compound CC(C)=CCCC(C)=CCCC(C)=CCCC=C(C)CCC=C(C)CCC=C(C)C YYGNTYWPHWGJRM-UHFFFAOYSA-N 0.000 description 3
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 3
- 239000004475 Arginine Substances 0.000 description 3
- 102000008186 Collagen Human genes 0.000 description 3
- 108010035532 Collagen Proteins 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
- 229920002683 Glycosaminoglycan Polymers 0.000 description 3
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 3
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 3
- 229920000388 Polyphosphate Polymers 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 229930182558 Sterol Natural products 0.000 description 3
- BHEOSNUKNHRBNM-UHFFFAOYSA-N Tetramethylsqualene Natural products CC(=C)C(C)CCC(=C)C(C)CCC(C)=CCCC=C(C)CCC(C)C(=C)CCC(C)C(C)=C BHEOSNUKNHRBNM-UHFFFAOYSA-N 0.000 description 3
- 235000018936 Vitellaria paradoxa Nutrition 0.000 description 3
- 241001135917 Vitellaria paradoxa Species 0.000 description 3
- 150000007513 acids Chemical class 0.000 description 3
- 208000026935 allergic disease Diseases 0.000 description 3
- 238000000540 analysis of variance Methods 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 3
- 239000004568 cement Substances 0.000 description 3
- 229920001436 collagen Polymers 0.000 description 3
- 230000002939 deleterious effect Effects 0.000 description 3
- 239000000975 dye Substances 0.000 description 3
- 150000002148 esters Chemical class 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 235000021588 free fatty acids Nutrition 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 230000009610 hypersensitivity Effects 0.000 description 3
- 230000008595 infiltration Effects 0.000 description 3
- 238000001764 infiltration Methods 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 238000001139 pH measurement Methods 0.000 description 3
- 239000002304 perfume Substances 0.000 description 3
- 239000011574 phosphorus Substances 0.000 description 3
- 229910052698 phosphorus Inorganic materials 0.000 description 3
- 239000001205 polyphosphate Substances 0.000 description 3
- 235000011176 polyphosphates Nutrition 0.000 description 3
- 229940057910 shea butter Drugs 0.000 description 3
- 230000008591 skin barrier function Effects 0.000 description 3
- 229940031439 squalene Drugs 0.000 description 3
- TUHBEKDERLKLEC-UHFFFAOYSA-N squalene Natural products CC(=CCCC(=CCCC(=CCCC=C(/C)CCC=C(/C)CC=C(C)C)C)C)C TUHBEKDERLKLEC-UHFFFAOYSA-N 0.000 description 3
- 235000003702 sterols Nutrition 0.000 description 3
- 150000003432 sterols Chemical class 0.000 description 3
- 239000004094 surface-active agent Substances 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 230000001755 vocal effect Effects 0.000 description 3
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 2
- 108020004465 16S ribosomal RNA Proteins 0.000 description 2
- YIWUKEYIRIRTPP-UHFFFAOYSA-N 2-ethylhexan-1-ol Chemical compound CCCCC(CC)CO YIWUKEYIRIRTPP-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 2
- 206010013786 Dry skin Diseases 0.000 description 2
- 102000016942 Elastin Human genes 0.000 description 2
- 108010014258 Elastin Proteins 0.000 description 2
- 102100028314 Filaggrin Human genes 0.000 description 2
- 101710088660 Filaggrin Proteins 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- 206010060800 Hot flush Diseases 0.000 description 2
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 2
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 2
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 description 2
- 244000062730 Melissa officinalis Species 0.000 description 2
- 235000010654 Melissa officinalis Nutrition 0.000 description 2
- 108010052285 Membrane Proteins Proteins 0.000 description 2
- MSFSPUZXLOGKHJ-UHFFFAOYSA-N Muraminsaeure Natural products OC(=O)C(C)OC1C(N)C(O)OC(CO)C1O MSFSPUZXLOGKHJ-UHFFFAOYSA-N 0.000 description 2
- 108010013639 Peptidoglycan Proteins 0.000 description 2
- 206010040880 Skin irritation Diseases 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 150000001335 aliphatic alkanes Chemical class 0.000 description 2
- 239000013566 allergen Substances 0.000 description 2
- 239000008346 aqueous phase Substances 0.000 description 2
- 235000013871 bee wax Nutrition 0.000 description 2
- 239000012166 beeswax Substances 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 239000004202 carbamide Substances 0.000 description 2
- 229940106189 ceramide Drugs 0.000 description 2
- 150000001783 ceramides Chemical class 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 239000000470 constituent Substances 0.000 description 2
- 229910052802 copper Inorganic materials 0.000 description 2
- 239000010949 copper Substances 0.000 description 2
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 2
- 235000018417 cysteine Nutrition 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 238000009792 diffusion process Methods 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 230000037336 dry skin Effects 0.000 description 2
- 235000013399 edible fruits Nutrition 0.000 description 2
- 229920002549 elastin Polymers 0.000 description 2
- 230000008030 elimination Effects 0.000 description 2
- 238000003379 elimination reaction Methods 0.000 description 2
- 239000003974 emollient agent Substances 0.000 description 2
- 231100000049 endocrine disruptor Toxicity 0.000 description 2
- 239000000598 endocrine disruptor Substances 0.000 description 2
- 230000007613 environmental effect Effects 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 230000001747 exhibiting effect Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 150000008131 glucosides Chemical class 0.000 description 2
- 230000036074 healthy skin Effects 0.000 description 2
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 2
- 239000003906 humectant Substances 0.000 description 2
- 229920002674 hyaluronan Polymers 0.000 description 2
- 229960003160 hyaluronic acid Drugs 0.000 description 2
- 230000000887 hydrating effect Effects 0.000 description 2
- 229930195733 hydrocarbon Natural products 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 230000001965 increasing effect Effects 0.000 description 2
- 238000011835 investigation Methods 0.000 description 2
- 229910052742 iron Inorganic materials 0.000 description 2
- 230000007794 irritation Effects 0.000 description 2
- 239000000865 liniment Substances 0.000 description 2
- -1 lipid triglycerides Chemical class 0.000 description 2
- 230000005923 long-lasting effect Effects 0.000 description 2
- 239000011777 magnesium Substances 0.000 description 2
- 229910052749 magnesium Inorganic materials 0.000 description 2
- 230000000813 microbial effect Effects 0.000 description 2
- 239000002773 nucleotide Substances 0.000 description 2
- 125000003729 nucleotide group Chemical group 0.000 description 2
- WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 2
- 150000002894 organic compounds Chemical class 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 239000013612 plasmid Substances 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 230000003014 reinforcing effect Effects 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 239000003352 sequestering agent Substances 0.000 description 2
- 230000036556 skin irritation Effects 0.000 description 2
- 231100000475 skin irritation Toxicity 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000007790 solid phase Substances 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 150000008163 sugars Chemical class 0.000 description 2
- 230000000475 sunscreen effect Effects 0.000 description 2
- 239000000516 sunscreening agent Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 210000004243 sweat Anatomy 0.000 description 2
- 210000000106 sweat gland Anatomy 0.000 description 2
- 210000002820 sympathetic nervous system Anatomy 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 239000011573 trace mineral Substances 0.000 description 2
- 235000013619 trace mineral Nutrition 0.000 description 2
- VLPFTAMPNXLGLX-UHFFFAOYSA-N trioctanoin Chemical compound CCCCCCCC(=O)OCC(OC(=O)CCCCCCC)COC(=O)CCCCCCC VLPFTAMPNXLGLX-UHFFFAOYSA-N 0.000 description 2
- 239000013598 vector Substances 0.000 description 2
- SERLAGPUMNYUCK-DCUALPFSSA-N 1-O-alpha-D-glucopyranosyl-D-mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O SERLAGPUMNYUCK-DCUALPFSSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- QWGRWMMWNDWRQN-UHFFFAOYSA-N 2-methylpropane-1,3-diol Chemical compound OCC(C)CO QWGRWMMWNDWRQN-UHFFFAOYSA-N 0.000 description 1
- QCDWFXQBSFUVSP-UHFFFAOYSA-N 2-phenoxyethanol Chemical compound OCCOC1=CC=CC=C1 QCDWFXQBSFUVSP-UHFFFAOYSA-N 0.000 description 1
- NCZPCONIKBICGS-UHFFFAOYSA-N 3-(2-ethylhexoxy)propane-1,2-diol Chemical compound CCCCC(CC)COCC(O)CO NCZPCONIKBICGS-UHFFFAOYSA-N 0.000 description 1
- 125000005274 4-hydroxybenzoic acid group Chemical class 0.000 description 1
- ODHCTXKNWHHXJC-VKHMYHEASA-N 5-oxo-L-proline Chemical compound OC(=O)[C@@H]1CCC(=O)N1 ODHCTXKNWHHXJC-VKHMYHEASA-N 0.000 description 1
- 244000144927 Aloe barbadensis Species 0.000 description 1
- 235000002961 Aloe barbadensis Nutrition 0.000 description 1
- 244000144725 Amygdalus communis Species 0.000 description 1
- 235000011437 Amygdalus communis Nutrition 0.000 description 1
- 241001116415 Balanophora Species 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 244000025254 Cannabis sativa Species 0.000 description 1
- 235000012766 Cannabis sativa ssp. sativa var. sativa Nutrition 0.000 description 1
- 235000012765 Cannabis sativa ssp. sativa var. spontanea Nutrition 0.000 description 1
- 239000005635 Caprylic acid (CAS 124-07-2) Substances 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- 244000060011 Cocos nucifera Species 0.000 description 1
- 235000013162 Cocos nucifera Nutrition 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 235000004866 D-panthenol Nutrition 0.000 description 1
- 239000011703 D-panthenol Substances 0.000 description 1
- SNPLKNRPJHDVJA-ZETCQYMHSA-N D-panthenol Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCCO SNPLKNRPJHDVJA-ZETCQYMHSA-N 0.000 description 1
- 206010012442 Dermatitis contact Diseases 0.000 description 1
- 238000001061 Dunnett's test Methods 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- 206010016334 Feeling hot Diseases 0.000 description 1
- 108700041153 Filaggrin Proteins Proteins 0.000 description 1
- 244000002175 Fouquieria splendens Species 0.000 description 1
- 235000011798 Fouquieria splendens Nutrition 0.000 description 1
- 208000003098 Ganglion Cysts Diseases 0.000 description 1
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 description 1
- 208000033830 Hot Flashes Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 235000010254 Jasminum officinale Nutrition 0.000 description 1
- 240000005385 Jasminum sambac Species 0.000 description 1
- LEVWYRKDKASIDU-IMJSIDKUSA-N L-cystine Chemical compound [O-]C(=O)[C@@H]([NH3+])CSSC[C@H]([NH3+])C([O-])=O LEVWYRKDKASIDU-IMJSIDKUSA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- 241000446313 Lamella Species 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 102000004895 Lipoproteins Human genes 0.000 description 1
- 108090001030 Lipoproteins Proteins 0.000 description 1
- PWHULOQIROXLJO-UHFFFAOYSA-N Manganese Chemical compound [Mn] PWHULOQIROXLJO-UHFFFAOYSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 235000021314 Palmitic acid Nutrition 0.000 description 1
- 235000008331 Pinus X rigitaeda Nutrition 0.000 description 1
- 235000011613 Pinus brutia Nutrition 0.000 description 1
- 241000018646 Pinus brutia Species 0.000 description 1
- 244000014047 Polianthes tuberosa Species 0.000 description 1
- 235000016067 Polianthes tuberosa Nutrition 0.000 description 1
- 239000004392 Polyglycitol syrup Substances 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 235000009827 Prunus armeniaca Nutrition 0.000 description 1
- 244000018633 Prunus armeniaca Species 0.000 description 1
- 241000220317 Rosa Species 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 240000000111 Saccharum officinarum Species 0.000 description 1
- 235000007201 Saccharum officinarum Nutrition 0.000 description 1
- 206010050637 Skin tightness Diseases 0.000 description 1
- 244000061456 Solanum tuberosum Species 0.000 description 1
- 235000002595 Solanum tuberosum Nutrition 0.000 description 1
- 240000006394 Sorghum bicolor Species 0.000 description 1
- 235000011684 Sorghum saccharatum Nutrition 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 239000005864 Sulphur Substances 0.000 description 1
- 208000005400 Synovial Cyst Diseases 0.000 description 1
- 102000003563 TRPV Human genes 0.000 description 1
- 108060008564 TRPV Proteins 0.000 description 1
- 208000003443 Unconsciousness Diseases 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 210000001789 adipocyte Anatomy 0.000 description 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 235000011399 aloe vera Nutrition 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 239000006286 aqueous extract Substances 0.000 description 1
- 125000000089 arabinosyl group Chemical group C1([C@@H](O)[C@H](O)[C@H](O)CO1)* 0.000 description 1
- 229960003121 arginine Drugs 0.000 description 1
- 125000004429 atom Chemical group 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 230000003796 beauty Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 235000014121 butter Nutrition 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 235000009120 camo Nutrition 0.000 description 1
- 239000004204 candelilla wax Substances 0.000 description 1
- 235000013868 candelilla wax Nutrition 0.000 description 1
- 229940073532 candelilla wax Drugs 0.000 description 1
- 235000013877 carbamide Nutrition 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical group 0.000 description 1
- 150000001735 carboxylic acids Chemical class 0.000 description 1
- 230000006037 cell lysis Effects 0.000 description 1
- 230000010267 cellular communication Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000019522 cellular metabolic process Effects 0.000 description 1
- 235000013339 cereals Nutrition 0.000 description 1
- 235000005607 chanvre indien Nutrition 0.000 description 1
- 150000005829 chemical entities Chemical class 0.000 description 1
- 230000001713 cholinergic effect Effects 0.000 description 1
- 238000005352 clarification Methods 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 239000013065 commercial product Substances 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 230000003750 conditioning effect Effects 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 208000010247 contact dermatitis Diseases 0.000 description 1
- 239000008271 cosmetic emulsion Substances 0.000 description 1
- 229940109239 creatinine Drugs 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 229960003067 cystine Drugs 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 230000002354 daily effect Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 210000001047 desmosome Anatomy 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 238000002003 electron diffraction Methods 0.000 description 1
- 238000000635 electron micrograph Methods 0.000 description 1
- 238000001493 electron microscopy Methods 0.000 description 1
- 230000008451 emotion Effects 0.000 description 1
- 238000004945 emulsification Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000002158 endotoxin Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- 229940009714 erythritol Drugs 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 239000012183 esparto wax Substances 0.000 description 1
- 229960004756 ethanol Drugs 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- 229940100524 ethylhexylglycerin Drugs 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 150000002194 fatty esters Chemical class 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 102000034240 fibrous proteins Human genes 0.000 description 1
- 108091005899 fibrous proteins Proteins 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 210000003495 flagella Anatomy 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 150000002303 glucose derivatives Chemical class 0.000 description 1
- 229930182478 glucoside Natural products 0.000 description 1
- 125000002791 glucosyl group Chemical group C1([C@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 1
- 229940074046 glyceryl laurate Drugs 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 229940087559 grape seed Drugs 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 239000011487 hemp Substances 0.000 description 1
- IUJAMGNYPWYUPM-UHFFFAOYSA-N hentriacontane Chemical compound CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCC IUJAMGNYPWYUPM-UHFFFAOYSA-N 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 238000005984 hydrogenation reaction Methods 0.000 description 1
- 125000004356 hydroxy functional group Chemical group O* 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 1
- 229960000367 inositol Drugs 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 210000003963 intermediate filament Anatomy 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- 231100000021 irritant Toxicity 0.000 description 1
- 239000002085 irritant Substances 0.000 description 1
- 239000000905 isomalt Substances 0.000 description 1
- 235000010439 isomalt Nutrition 0.000 description 1
- HPIGCVXMBGOWTF-UHFFFAOYSA-N isomaltol Natural products CC(=O)C=1OC=CC=1O HPIGCVXMBGOWTF-UHFFFAOYSA-N 0.000 description 1
- 229940119170 jojoba wax Drugs 0.000 description 1
- 230000003780 keratinization Effects 0.000 description 1
- 210000005128 keratinized epithelium Anatomy 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 150000003893 lactate salts Chemical class 0.000 description 1
- 239000000832 lactitol Substances 0.000 description 1
- 235000010448 lactitol Nutrition 0.000 description 1
- VQHSOMBJVWLPSR-JVCRWLNRSA-N lactitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-JVCRWLNRSA-N 0.000 description 1
- 229960003451 lactitol Drugs 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 229920006008 lipopolysaccharide Polymers 0.000 description 1
- 150000004668 long chain fatty acids Chemical class 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 239000000845 maltitol Substances 0.000 description 1
- 235000010449 maltitol Nutrition 0.000 description 1
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 1
- 229940035436 maltitol Drugs 0.000 description 1
- 229910052748 manganese Inorganic materials 0.000 description 1
- 239000011572 manganese Substances 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 229960001855 mannitol Drugs 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 210000002752 melanocyte Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 229940100573 methylpropanediol Drugs 0.000 description 1
- 238000011169 microbiological contamination Methods 0.000 description 1
- 238000009629 microbiological culture Methods 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 239000012184 mineral wax Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 108091008700 nociceptors Proteins 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- 235000008935 nutritious Nutrition 0.000 description 1
- 229960002446 octanoic acid Drugs 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 238000013021 overheating Methods 0.000 description 1
- 125000000913 palmityl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 235000019809 paraffin wax Nutrition 0.000 description 1
- 230000037368 penetrate the skin Effects 0.000 description 1
- 230000008447 perception Effects 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 235000019271 petrolatum Nutrition 0.000 description 1
- 229960005323 phenoxyethanol Drugs 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- 150000003018 phosphorus compounds Chemical class 0.000 description 1
- 229940068065 phytosterols Drugs 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 229920000058 polyacrylate Polymers 0.000 description 1
- 235000019451 polyglycitol syrup Nutrition 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- ZRHANBBTXQZFSP-UHFFFAOYSA-M potassium;4-amino-3,5,6-trichloropyridine-2-carboxylate Chemical compound [K+].NC1=C(Cl)C(Cl)=NC(C([O-])=O)=C1Cl ZRHANBBTXQZFSP-UHFFFAOYSA-M 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 229930010796 primary metabolite Natural products 0.000 description 1
- 239000006041 probiotic Substances 0.000 description 1
- 230000000529 probiotic effect Effects 0.000 description 1
- 235000018291 probiotics Nutrition 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 229940079889 pyrrolidonecarboxylic acid Drugs 0.000 description 1
- ARIWANIATODDMH-UHFFFAOYSA-N rac-1-monolauroylglycerol Chemical compound CCCCCCCCCCCC(=O)OCC(O)CO ARIWANIATODDMH-UHFFFAOYSA-N 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000002787 reinforcement Effects 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 230000031070 response to heat Effects 0.000 description 1
- 230000000284 resting effect Effects 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 1
- 229930000044 secondary metabolite Natural products 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000021317 sensory perception Effects 0.000 description 1
- 210000002265 sensory receptor cell Anatomy 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 235000021391 short chain fatty acids Nutrition 0.000 description 1
- 150000004666 short chain fatty acids Chemical class 0.000 description 1
- 210000004927 skin cell Anatomy 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 229940083608 sodium hydroxide Drugs 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 150000005846 sugar alcohols Polymers 0.000 description 1
- 150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
- 235000020238 sunflower seed Nutrition 0.000 description 1
- 150000003505 terpenes Chemical class 0.000 description 1
- 235000007586 terpenes Nutrition 0.000 description 1
- 229930003799 tocopherol Natural products 0.000 description 1
- 229960001295 tocopherol Drugs 0.000 description 1
- 235000010384 tocopherol Nutrition 0.000 description 1
- 239000011732 tocopherol Substances 0.000 description 1
- LOIYMIARKYCTBW-OWOJBTEDSA-N trans-urocanic acid Chemical compound OC(=O)\C=C\C1=CNC=N1 LOIYMIARKYCTBW-OWOJBTEDSA-N 0.000 description 1
- LOIYMIARKYCTBW-UHFFFAOYSA-N trans-urocanic acid Natural products OC(=O)C=CC1=CNC=N1 LOIYMIARKYCTBW-UHFFFAOYSA-N 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
- 239000000341 volatile oil Substances 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
- 125000000969 xylosyl group Chemical group C1([C@H](O)[C@@H](O)[C@H](O)CO1)* 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
- A61K8/04—Dispersions; Emulsions
- A61K8/06—Emulsions
- A61K8/062—Oil-in-water emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/34—Alcohols
- A61K8/342—Alcohols having more than seven atoms in an unbroken chain
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/34—Alcohols
- A61K8/345—Alcohols containing more than one hydroxy group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/36—Carboxylic acids; Salts or anhydrides thereof
- A61K8/365—Hydroxycarboxylic acids; Ketocarboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/37—Esters of carboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/60—Sugars; Derivatives thereof
- A61K8/604—Alkylpolyglycosides; Derivatives thereof, e.g. esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/63—Steroids; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/73—Polysaccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/73—Polysaccharides
- A61K8/735—Mucopolysaccharides, e.g. hyaluronic acid; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/92—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof
- A61K8/922—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof of vegetable origin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/99—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from microorganisms other than algae or fungi, e.g. protozoa or bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/007—Preparations for dry skin
Definitions
- TITLE New emulsion that mimics the skin
- the present invention relates to cosmetic compositions in the form of emulsions containing ingredients similar to those present in the skin, in order to best respect the structural organization of the skin.
- Emulsions are thus composed of two phases, an aqueous phase composed among others of water, hydrolysates and aqueous extracts and an oily phase composed among others of oils, waxes, butters and fatty alcohol.
- the two phases are emulsified using surfactants.
- active ingredients i.e. the pleasure and perception, the color, the smell of the product, the stability of the whole, its protection over time, its cosmetic effectiveness. immediate and longer term.
- the skin is a protective envelope that covers the entire body. It is the largest and heaviest organ in the human body. Its thickness varies from 0.5mm (neck) to 5mm (soles of the feet). It is covered with a hydrolipidic protective film, made of a mixture of secretions such as sweat and sebum.
- the skin has an essential protective role, it also acts as a communication interface between the body and its surrounding environment, thanks to the many tactile, thermal and nociceptor receptors it contains.
- the skin is composed of three layers, the epidermis, the dermis and the hypodermis (going from the outside to the inside of the body) associated with different structures called cutaneous appendages (nails, hair/hair, glands) .
- the epidermis is made up of a stratified, cobblestone, keratinized epithelium. It is not vascularized, unlike the dermis and the hypodermis.
- the epidermis is mainly composed of keratinocytes, which constantly proliferate and differentiate. There are 4 different layers in the epidermis, depending on the stage of differentiation of the keratinocytes which compose: the basal layer (at the level of the junction with the dermis), spinous, granular and horny, also called stratum comeum (in contact with the external environment).
- stratum comeum in contact with the external environment.
- the cells of the stratum corneum, the comeocytes end up detaching by forming scales, allowing the renewal of the epidermis.
- Keratinocytes represent the most abundant cell type in the epidermis. These are cells characterized by the abundant presence of keratin, a fibrous protein rich in cysteine. The keratin molecules are linked together by disulphide bridges, which gives rigidity and impermeability to the epidermis. The keratinocytes are firmly bound together by desmosomes, they differentiate as they pass through the different layers of the epidermis.
- lipid granules When they pass through the granular layer, they become loaded with lipid granules (Odland bodies) and grains rich in proteins such as profilaggrin.
- This protein is the precursor of filaggrin, which is involved in the keratinization of cells, the keratinocytes flatten and end up losing their nucleus. They die and become comeocytes which bathe in a lipid cement originating from the lipids of the Odland bodies. This is made up of free fatty acids, ceramides, triglycerides and cholesterol. If the comeocytes are said to be dead, they remain biochemically active. It is the presence of the natural Hydration factor (NMF) that allows it.
- NMF Natural Hydration factor
- Filaggrin is found proteolyzed into free amino acids, urocanic acid and pyrrolidone carboxylic acid in comeocytes. These chemical entities, grouped together under the term NMF will play the role of humectant within the comeocyte cytoplasm, retaining water there. Maintaining a minimum hydration level in the cell allows the enzymes present there to maintain their enzymatic activities.
- the keratinocytes and the lipid cement form a real barrier to the passage of many molecules.
- Melanocytes are scarce cells in the epidermis, they produce melanin which aims to filter UV rays.
- the dermis is a connective, vascularized and innervated tissue located under the epidermis. It is 10 to 40 times thicker than this one. It is composed mainly of protein fibers of elastin and collagen, bathed in an aqueous gel of glycosaminoglycans, such as hyaluronic acid. These make it possible to retain a high proportion of water within it, the dermis being composed of 80% water. This gel formed by water and glycosaminoglycans is able to absorb the shocks to which the skin is exposed, while the collagen fibers and of elastin give it elasticity and resistance. Thus, the dermis acts as a mechanical, flexible and compressible support tissue for the skin.
- the hypodermis is the deepest and thickest layer of the skin. It is part of the continuity of the dermis without any real separation between the two tissues. It is also like the latter, a connective tissue, innervated and vascularized.
- the hypodermis forms a cushion that acts as a mechanical protection for the underlying structures. This fatty layer also helps insulate the body from thermal variations. If the dermis can be considered as a water reserve, the fats stored within the adipocytes of the hypodermis constitute an energy reserve.
- Healthy skin comprises on average 70% water, its distribution varying according to the layer, 27.5% proteins (amino acids, proteins, hormones and enzymes), 2% lipids (phospholipids, fatty acids, triglycerides ..), 0.5% of mineral salts and trace elements (sodium, magnesium, potassium, iron, copper, zinc, sulphur, phosphorus, iodine, manganese).
- the surface cutaneous film of the skin is composed of the hydrolipidic film (sebum, sweat, water, lipids).
- the stratum corneum is particularly rich in NMF (Natural Moisturizing Factor), the main molecules are glycerol, urea, amino acids, lactates, sugars.
- NMF Natural Moisturizing Factor
- the composition of the superficial layers of the epidermis is rich in water, amino acids, polysaccharides, lipids, peptides, proteins (collagens), mineral salts, vitamins and hyaluronic acid.
- Document EP 3443949 describes a composition of the multi-lamellar emulsion type which mimics the composition of the skin.
- This composition contains compounds derived from phosphorus such as polyphosphates and phospholipids in order to form the layers. Phosphorus compounds are controversial, however.
- cosmetic compositions comprising only physio-mimetic compounds perfectly respect the organization of the lipid matrix of the stratum corneum and even make this structural organization of the lipids more compact, thus allowing a reinforcement of the lipid barrier. skin.
- the invention relates to a cosmetic composition in the form of an oil-in-water emulsion, having in particular a multi-lamellar structure, comprising:
- At least one essential lipid chosen from the group comprising hydrogenated vegetable oils, in particular vegetable squalane, vegetable waxes, ethylhexyl palmitate and mixtures thereof,
- At least one hydroxy acid chosen from the group comprising alpha hydroxy acids, beta hydroxy acids, as well as mixtures thereof,
- at least one amino acid optionally at least one compound chosen from minerals,
- at least one vitamin optionally at least one vitamin, De water and
- at least one dermo-cosmetic active ingredient optionally at least one hydroxy acid chosen from the group comprising alpha hydroxy acids, beta hydroxy acids, as well as mixtures thereof,
- at least one amino acid optionally at least one compound chosen from minerals, Optionally at least one vitamin, De water and optionalally at least one dermo-cosmetic active ingredient.
- a multi-lamellar emulsion is an oil-in-water (O/W) emulsion showing a multi-lamellar structure.
- Multi-lamellar emulsions have a multilayer structure; this is clearly visible on emulsion particles formed after emulsification, cut by freezing and then observed under an electron microscope. It is thus observed that each emulsion particle has a structure in the form of multiple layers.
- a multi-lamellar emulsion exhibits a lamellar structure, a structure which is also observed in the stratum corneum, defined as a plaque showing several layers of this lamellar structure, and offers skin moisturizing effects by reinforcing the natural barrier function of the skin. .
- the compositions according to the invention comprise at least one alkylglycoside.
- a suitable alkylglycoside, preferably agro-based, can be chosen in particular from the alkyl-(poly)glycosides of general formula
- Alk denotes a hydrophobic aliphatic hydrocarbon fragment, saturated or unsaturated, linear or branched comprising from 3 to 22 carbon atoms
- Z represents a hydrophilic glycoside group, for example such as glucose, xylose or arabinose, and
- Z represents a glucose group.
- Z represents a xylose group.
- Z represents an arabinose group.
- Alk denotes an aliphatic hydrophobic hydrocarbon fragment, saturated or unsaturated, linear or branched comprising 6 to 22 carbon atoms.
- Alk denotes an aliphatic hydrophobic hydrocarbon fragment, saturated or unsaturated, linear or branched comprising 8 to 20 carbon atoms.
- Alk denotes an aliphatic hydrophobic hydrocarbon fragment, saturated or unsaturated, linear or branched comprising 10 to 20 carbon atoms.
- Alk denotes an aliphatic hydrophobic hydrocarbon fragment, saturated or unsaturated, linear or branched comprising 12 to 20 carbon atoms.
- a suitable alkylglycoside can be chosen from the group comprising cetearyl glucoside, for example contained in the commercial product sold under the name Montano v® 68.
- compositions according to the invention comprise at least one polysaccharide. It's about polymers of the carbohydrate family made up of several oses linked together by osidic bonds. They are constituents of skin cells, they have a function in cellular metabolism by supplying energy, they also have a structuring role, in particular in the skin barrier function.
- the at least one polysaccharide suitable for the invention may be chosen in particular from the group comprising xanthan gum, pullulan, sclerotium gum, tara gum, acacia gum, sodium hyaluronate and mixtures thereof.
- the polysaccharide present in the composition according to the invention is xanthan gum.
- the cosmetic composition according to the invention comprises from 0.05 to 2% by weight, in particular from 0.05 to 0.5% by weight and more particularly from 0.1 to 0.3% by weight of at least one polysaccharide, relative to the total weight of the composition.
- compositions according to the invention comprise at least one triglyceride.
- Triglycerides are composed of three fatty acids esterified to one molecule of glycerol. They are found among the lipids of sebum, their main roles are to nourish the skin and lubricate it.
- the triglycerides suitable for the invention can be chosen in particular from the group comprising triglycerides esterified with C8-C18 fatty acids, in particular with C10-C18 fatty acids, more particularly still caprylic acid.
- the triglyceride present in the composition according to the invention is caprylic triglyceride, that is to say glycerol tricaprylate.
- the cosmetic composition according to the invention comprises from 1 to 40% by weight, in particular from 5 to 35% by weight and more particularly from 10 to 30% by weight of triglycerides, relative to the total weight of the composition.
- compositions according to the invention comprise at least one fatty alcohol, this being an alcohol with a long carbon chain having, in general, an even number of carbon atoms.
- Fatty alcohols are fatty waxy substances which have interesting properties in cosmetics, in particular film-forming, emollient, moisturizing, softening and protective.
- the at least one fatty alcohol suitable for the invention may be chosen in particular from the group comprising lauryl alcohol, myristyl alcohol, cetyl alcohol, stearyl alcohol, behenyl alcohol, as well as mixtures thereof.
- cetearyl alcohol which is a mixture of cetyl and stearyl alcohol.
- the fatty alcohol present in the composition according to the invention is cetearyl alcohol.
- the fatty alcohol, cetearyl alcohol is derived from material of solely vegetable origin, for example oil of coconut. Mention may be made, by way of example, as a source of fatty alcohol such as cetearyl alcohol - additionally containing an alkylglycoside of plant origin - the nonionic surfactant MONTANOV 68® (SEPPIC).
- a source of fatty alcohol such as cetearyl alcohol - additionally containing an alkylglycoside of plant origin - the nonionic surfactant MONTANOV 68® (SEPPIC).
- the cosmetic composition according to the invention comprises from 0.1 to 10% by weight, in particular from 0.5 to 10% by weight and more particularly from 2 to 6% by weight of fatty alcohol, relative to the total weight of the composition.
- compositions according to the invention comprise at least one polyol, also called polyalcohol, which is an organic compound characterized by a certain number of hydroxyl groups.
- the polyol suitable for the invention can be chosen from the group comprising glycerol (or glycerin), sorbitol, xylitol, isomalt, mannitol, maltitol, lactitol, erythritol, polyglycitol syrup, and their mixtures.
- the polyol present in the composition according to the invention is glycerol, the moisturizing agent par excellence.
- the cosmetic composition according to the invention comprises from 0.5 to 20% by weight, in particular from 1 to 15% by weight and more particularly from 2 to 10% by weight of at least one polyol, relative to the total weight of the composition.
- compositions according to the invention comprise at least one phytosterol or natural sterol.
- These are plant lipids that have a structure very similar to cholesterol, present mainly in vegetable oils and/or waxes, oilseeds or even shea butter, for example.
- the phytosterol present in the composition according to the invention thus comes from shea butter and/or from a wax; more particularly a shea butter particularly rich in these sterols.
- the cosmetic composition according to the invention comprises from 0.04 to 10% by weight, in particular from 0.1 to 10% by weight and more particularly from 1 to 5% by weight of at least one phytosterol, relative to the total weight of the composition.
- compositions according to the invention comprise at least one essential lipid. These compounds are present in the skin, their role is to act in cell cohesion, they are therefore important in repair. Mention may be made, as essential lipids, of hydrogenated vegetable oils including vegetable squalane, vegetable or animal waxes, ethylhexyl palmitate, and mixtures thereof.
- Squalane is a hydrocarbon derived from the hydrogenation of squalene. Contrary to squalene, due to the complete saturation of squalane, it is not subject to autooxidation. Squalane is an oil that has many affinities with the skin, it is indeed one of the main components of sebum.
- a wax including vegetable waxes, but also animal and mineral waxes such as paraffin waxes, is generally a mixture of alkanes, fatty esters of fatty acids, fatty alcohols, fatty acids and very long chain hydrocarbons (C10-C30); in particular a wax can be comprising esters of ethylene glycol and fatty acids, in particular a monoester of fatty acid and long chain alcohol (for example, C10-C22) but also various compounds such as terpenes and sterols.
- the wax is therefore a vegetable wax and this can be chosen, for example, from the group comprising Candelilla wax, Camauba wax, sunflower seed wax, beeswax, rice bran, sugarcane wax, grapeseed wax, jojoba wax, sorghum seed wax, ouiricuri wax, pea leaf wax, potato leaf wax , Esparto Wax, Ocotillo Wax, Balanophora Wax, Attier Wax, Sea Rye Wax, Cherry Laurel Wax, Oak Wax, Mimosa Wax, Wax orange blossom wax, jasmine wax, rose wax, hemp wax, apricot wax, tuberose wax, orange wax, sweet almond wax, needle wax pine and mixtures thereof.
- a vegetable wax can be a wax derived from the aerial parts of plants, leaves, stems, flowers or fruits.
- the wax can be an animal wax and beeswax can be particularly advantageous.
- Vegetable and animal waxes are essentially made up of compounds that can be schematically divided into three groups. In the first, we will find the most common compounds of the alkane type; a second group concerns compounds such as ketones, fatty alcohols, esters, free fatty acids, phytosterols and resins. Ethylhexyl palmitate is an ester of 2-ethylhexanol and palmitic acid.
- the cosmetic composition according to the invention comprises from 0.1 to 30% by weight, in particular from 1 to 20% by weight and more particularly from 2 to 15% by weight of at least one essential lipid , relative to the total weight of the composition.
- compositions according to the invention may comprise at least one hydroxy acid chosen from the group comprising alpha hydroxy acids, beta hydroxy acids, as well as mixtures thereof.
- ⁇ -Hydroxy acids are carboxylic acids derived from fruit or milk sugars. At low concentration (less than 1%) they are hydrating. So advantageously, the alpha hydroxy acid is chosen from the group comprising lactic acid, malic acid, tartaric acid, citric acid and mixtures thereof.
- O-hydroxy acids are organic compounds that contain a carboxylic acid functional group, and a hydroxy functional group in the beta position.
- the cosmetic composition according to the invention comprises citric acid.
- the compositions according to the invention may comprise from 0 to 1% by weight, in particular from 0.01 to 0.5% by weight and more particularly from 0.01 to 0.05% by weight of at least one hydroxy acid, relative to the total weight of the composition.
- compositions according to the invention may comprise at least one amino acid. They are small nitrogen-rich molecules that make up proteins. Amino acids are hydrating and nutritious. Cells can use them to make proteins.
- the at least one amino acid can be chosen from the group comprising arginine, cysteine, cystine, tyrosine, as well as mixtures thereof, for example.
- the cosmetic composition according to the invention comprises arginine.
- the compositions according to the invention may comprise from 0 to 3% by weight, in particular from 0.05 to 2% by weight and more particularly from 0.1 to 1% by weight of at least one amino acid , relative to the total weight of the composition.
- compositions according to the invention may comprise at least one vitamin.
- the at least one vitamin can be selected from the group comprising vitamin E, vitamin A, vitamin F, provitamin B5, vitamin C, and mixtures thereof.
- the cosmetic composition according to the invention may comprise from 0 to 2% by weight, in particular from 0.01 to 1% by weight of at least one vitamin, relative to the total weight of the composition.
- compositions according to the invention may comprise at least one dermo-cosmetic active ingredient.
- the optional dermo-cosmetic active ingredient of the compositions according to the invention can be any active ingredient endowed with dermatological, cosmetic or dermo-cosmetic properties. It may be a dermo-cosmetic active ingredient chosen from the group comprising a natural product, a plant extract, an extract derived from biotechnology (culture of plant cells or microalgae), a chemical product, or even a postbiotic, or of a combination of these this.
- postbiotic refers to a mixture of factors, products or metabolites, secreted by a living microorganism (usually a living bacterium) or released after lysis of said microorganism.
- a postbiotic includes various elements such as, for example, enzymes, peptides, teichoic acids, peptidoglycan-derived muropeptides, polysaccharides, lipoproteins, cell surface proteins and organic acids, for example.
- Postbiotics thus correspond to mixtures of molecules resulting from a probiotic culture process (bacteria and/or yeasts) and more broadly to all the more or less soluble factors, products or metabolic by-products secreted by micro-organisms, then excreted or released into the medium after their lysis (short chain fatty acids, cellular fractions, functional proteins, extracellular polysaccharides, teichoic acid, peptidoglycan, etc.).
- a postbiotic, within the meaning of the present invention corresponds to an extract resulting from a culture and/or lysis of a microbial culture, in particular bacterial.
- the exact composition of a postbiotic is not precisely determined and depends on the microorganism, the culture conditions and also the lysis and purification conditions.
- the dermo-cosmetic active ingredient when present, is a postbiotic and is a bacterial extract originating from a bacterium belonging to the class of proteobacteria, in particular of the class of beta-proteobacteria.
- the bacterial extract comes from a bacterium belonging to the Neisseriaceae subfamily.
- the postbiotic is a bacterial extract from a bacterium named LMB64, filed with the CNCM on April 8, 2010 under the reference 1-4290 and described in patent application WO2012/085182.
- the invention thus relates to a cosmetic composition, characterized in that the dermo-cosmetic active ingredient is a postbiotic and is a bacterial extract originating from a bacterium belonging to the class of proteobacteria, in particular of the class of beta-proteobacteria, in particular a bacterium belonging to the Neisseriaceae subfamily.
- the postbiotic is a bacterial extract obtained from a suspension of a non-pathogenic gram-negative bacterium belonging to the class of beta-proteobacteria, subfamily Neisseriaceae, the nucleotide sequence of the gene of 16S rRNA of said bacterium comprises the sequence SEQ ID No. 1; wherein said extract is composed of membrane proteins, lipopolysaccharides, proteins periplasmic, protein fragments from the flagellum and primary and secondary metabolites produced by the bacterium, said bacterium comprising at least one plasmid comprising the sequence SEQ ID No. 2, or any sequence having at least 80% identity with said sequence SEQ ID No.
- the bacterium in which the bacterium is deposited at the CNCM on April 8, 2010 under the reference 1-4290 and further characterized in that the bacterium is non-filamentous and in which said bacterial extract comprises a fraction obtainable by leaving the bacteria culture medium, containing the bacterial cells, to incubate and react in a basic medium (for example at a pH between 8 and 12, more particularly between 9 and 11), then by clarifying the medium in order to obtain a clear solution comprising, or constituting, the extract in question.
- a basic medium for example at a pH between 8 and 12, more particularly between 9 and 11
- the clarification can be carried out by leaving the extract at low temperature at basic pH, for example for a time ranging from a few tens of minutes to several hours, for example 2 to 10 hours, in particular 5 hours and this at a temperature of 2 at 10°C, for example at 4°C, then by decanting, filtering or centrifuging, in particular by centrifuging and filtering at 0.2 ⁇ m, in order to obtain the clear solution representing the extract comprising the postbiotic .
- the postbiotic is a bacterial extract obtained from a suspension of a non-pathogenic gram-negative bacterium belonging to the class of beta-proteobacteria, subfamily Neisseriaceae, the nucleotide sequence of the gene of the 16S rRNA of said bacterium comprises the sequence SEQ ID No. 1; wherein said extract is obtained by a process comprising the steps of:
- Said bacterium comprises at least one plasmid comprising the sequence SEQ ID No. 2, or any sequence exhibiting at least 80% identity with said sequence SEQ ID No. 2, and the bacterium is deposited at the CNCM on April 8, 2010 under the reference 1-4290 and is further characterized in that the bacterium is non-filamentous.
- the cosmetic composition according to the invention comprises from 0.01 to 2% of postbiotic by dry weight of postbiotic, in % by weight relative to the weight of the composition.
- the dermo-cosmetic active ingredient when present in the composition according to the invention, is an active ingredient providing immediate relief by acting on the hyper-reactive sensory fibers, which are responsible for feelings of overheating, tingling or itching typical of hypersensitive skin.
- the inventors Due to the multi-lamellar structure of the composition according to the invention, the inventors have noted a rapid and immediate effect of the active ingredient when the composition comprising it is applied. Without being bound by the theory, the inventors argue that this particular structure of the composition according to the invention, mimicking the structure of the skin, allows rapid passage and easier integration of the active ingredient of the composition within the skin.
- composition according to the invention constitutes a kind of vector of active ingredient by facilitating the in-situ delivery of said active ingredient to the site of action, thus allowing rapid and almost instantaneous action.
- the invention relates to a method for delivering a dermo-cosmetic active ingredient to the skin of a person in need, comprising the application of a composition according to the invention which comprises said dermo-cosmetic active ingredient.
- the skin of the person on which the cosmetic composition containing the dermo-cosmetic active ingredient is non-pathological skin, that is to say showing no lesions, damage or wounds.
- a cosmetic composition according to the invention contains a dermo-cosmetic active ingredient which may be 4-t-butylcyclohexanol, advantageously combined with pentylene glycol.
- a dermo-cosmetic active ingredient which may be 4-t-butylcyclohexanol, advantageously combined with pentylene glycol.
- the optional dermo-cosmetic active ingredient of a composition according to the invention can be the product marketed under the Symsitive brand, which is a combination of pentylene glycol and 4-t-butylcyclohexanol.
- 4-t-Butylcyclohexanol acts as a sensitizer regulator and a soothing active ingredient. It acts at the level of cellular communication by connecting directly with a specific TRPV 1 neuroreceptor. its regulatory action. It reduces sensitive symptoms and significantly burning and stinging.
- the water represents, in% by weight, from 5 to 95%, or even from 10 to 90%, particularly from 40 to 80%, even more particularly from 50 to 70%, of the composition.
- compositions according to the invention there are no components, however usual in conventional emulsions, such as preservatives, certain surfactants, phospholipids, polyphosphates, acrylic polymers (gelling agents ), perfumes, dyes, or even sequestering agents (EDTA).
- preservatives such as preservatives, certain surfactants, phospholipids, polyphosphates, acrylic polymers (gelling agents ), perfumes, dyes, or even sequestering agents (EDTA).
- phospholipids such as preservatives, certain surfactants, phospholipids, polyphosphates, acrylic polymers (gelling agents ), perfumes, dyes, or even sequestering agents (EDTA).
- Preservatives are ingredients capable of destroying germs that can contaminate beauty products.
- the most widely used in the cosmetics industry are parabens, MIT, phenoxyethanol, benzyl alcohol, formalin precursors. .. They are a source of skin intolerance and can be endocrine disruptors.
- Surfactants sulphates, betaines, poly-glucosides stabilize the emulsion and prevent separation into two phases. However, some can be irritating causing contact dermatitis because they alter the barrier function of the skin.
- Perfumes natural or not, like most essential oils, contain allergens. Their role is to bring an olfactory pleasure during the application of the cosmetic product. But allergens are sources of skin irritation and intolerance. Dyes have the same characteristics and should ideally be avoided for similar reasons.
- Synthetic gelling agents make it possible to adjust the viscosity and stabilize the emulsions. However, they are liquid plastics, difficult to biodegrade, film-forming and vectors of impurities.
- compositions according to the invention still combine in a structured, multi-lamellar emulsified medium as shown in example 2.
- the inventors conclude that the presence of an alkylglycoside contained in the composition according to the invention allows a lamellar organization.
- These compositions surprisingly have a structure of lamellae similar to the lamellae of the different layers of the skin. Instead of having as usual in the skin a dispersion of one phase in another in the form of microdroplets, the spatial organization is done in the form of lamellae. This translates at the time of application to the skin by a rapid fusion leaving no residue, proof of the perfect affinity of the product for the superficial layers of the skin.
- the composition according to the invention consists of lamellar phases in which the components, in particular the alkylglycoside molecules, are organized into planar bilayers called lamellae. These bilayers form a periodic stack, each lamella being separated from the others by an intermediate layer of water, this aqueous phase comprising in particular the dermo-cosmetic active ingredient(s) when present if water-soluble.
- compositions according to the invention can be in a form chosen from a fluid emulsion, a rich emulsion, a balm, a serum, a cream, whether for the face or for the body.
- the variation in the proportion of the ingredients makes it possible to obtain very different viscosities and fluidities.
- compositions according to the invention can be sprayable in particular for a sunscreen product or a lotion. It is the organization in lamellar structure which confers these various properties. This distribution facilitates the distribution on the skin but also on the keratinous structures on larger surfaces.
- compositions according to the invention allow easy distribution of a lower dose of product, compared to a conventional product.
- the emulsion conditioning device can be an airless tube with pump, a preci-tube, a spray, a bead applicator or an airless jar.
- the smell of the compositions according to the invention is that of its own constituents.
- the present invention also relates to a method of non-therapeutic cosmetic treatment comprising the application of a composition according to the invention to the skin or the scalp to improve its state of hydration.
- the composition used does not contain any dermo-cosmetic active ingredient.
- the present invention also relates to a method of non-therapeutic cosmetic treatment comprising the application of a composition according to the invention to the skin or the scalp to reinforce the barrier function of the skin or the scalp.
- the method according to the invention makes it possible to significantly reduce a disorder chosen from skin irritability, tingling, the burning sensation, the sensation of heat, tightness of the skin, itching, general discomfort, redness and dryness, taken alone or in combination.
- the present invention also relates to a method of non-therapeutic cosmetic treatment comprising the application of a composition according to the invention to the skin to reduce skin discomfort, in particular in a person having sensitive skin.
- Sensitive skin is reflected, in the foreground, by subjective signs of skin discomfort such as tingling, burning sensations, tingling, or even tightness. In the case of sensitive skin, reactive to cosmetics, these subjective signs may appear immediately after application of the product or a few hours later.
- the reduction of skin discomfort is understood, within the meaning of the present invention, as the limitation or reduction of at least one sign associated with this skin discomfort, chosen from the group comprising tingling, burning sensations, tingling, tugging and a combination thereof.
- the composition according to the invention integrates perfectly into the stratum comeum and makes it possible to preserve the skin and limit the signs of skin discomfort.
- compositions according to the invention by virtue of their structure and their composition, perfectly respect the organization or the lipid matrix of the stratum corneum. This characteristic allows the compositions according to the invention to be exceptionally well tolerated, they are therefore very well suited for applications on sensitive or even hypersensitive skin.
- the present invention also relates to a non-therapeutic cosmetic treatment method comprising the application of a composition according to the invention to the skin or the scalp to reinforce the lipid barrier of the skin or the scalp.
- the present invention relates to a method of cosmetic treatment comprising the application of a composition according to the invention to the skin for the protection of the organization of the Stratum corneum. More particularly, the composition used in such a method does not contain any dermo-cosmetic active ingredient.
- the present invention relates to a method of cosmetic treatment comprising the application of a composition according to the invention to the skin for the protection of the lipid matrix of the Stratum corneum.
- a cosmetic treatment method implementing the composition according to the invention may be such that the composition does not include any dermo-cosmetic active ingredient.
- the present invention relates to a cosmetic, non-therapeutic treatment method for dry skin, tight skin, sensitive skin, comprising the application of a composition according to the invention.
- the skin does not present a pathological aspect when the cosmetic method is implemented.
- the term use is understood to mean a non-therapeutic use, the application to healthy skin, that is to say skin showing no signs of pathological condition; in particular, the composition used may not contain any dermo-cosmetic active ingredient.
- the invention also relates to a composition according to the invention, comprising a dermo-cosmetic active ingredient, for its use for the treatment of an inflammatory skin disorder.
- the inflammatory skin disorder is chosen from the group comprising dermatitis, pruritus, eczema, psoriasis and rosacea.
- the invention thus relates to a composition according to the invention, comprising a dermo-cosmetic active ingredient, for its use for delivering said dermo-cosmetic active ingredient to the skin of a person requiring it.
- the person has skin exhibiting at least one pathological aspect of the inflammatory disorder type and this inflammatory disorder can be chosen from the group comprising dermatitis, pruritus, eczema, psoriasis and rosacea.
- this inflammatory disorder can be chosen from the group comprising dermatitis, pruritus, eczema, psoriasis and rosacea. Thanks to its particular structure, the composition according to the invention allows targeted, rapid delivery and thus an almost immediate effect on the symptoms associated with inflammatory disorders such as those mentioned above. The relief effect is thus almost instantaneous while being long-lasting.
- the invention relates to a composition according to the invention for its use for the treatment of a disorder chosen from the group comprising desquamation, edema, oozing, and crusts, taken alone or in combination.
- the inflammatory skin disorder is rosacea and the dermo-cosmetic active ingredient included in the composition is 4-t-butylcyclohexanol, advantageously combined with pentylene glycol, as described above.
- Non-therapeutic cosmetic treatment method comprising the application of a composition according to the invention to the skin or the scalp to improve its state of hydration comprising the application to the skin or the scalp of a cosmetic composition in the form of an oil-in-water emulsion, having in particular a multi-lamellar structure, comprising:
- At least one essential lipid chosen from the group comprising hydrogenated vegetable oils, in particular vegetable squalane, vegetable waxes, ethylhexyl palmitate and mixtures thereof,
- At least one hydroxy acid chosen from the group comprising acids alpha hydroxylated, beta hydroxylated acids, as well as their mixtures,
- At least one dermo-cosmetic active ingredient At least one dermo-cosmetic active ingredient.
- Embodiment 2 Method according to embodiment 1, characterized in that the alkylglycoside is chosen from the alkyl-(poly)glycosides of general formula Alk-O-Zp, in which:
- Alk denotes a hydrophobic aliphatic hydrocarbon fragment, saturated or unsaturated, linear or branched comprising from 3 to 22 carbon atoms, and
- - Z represents a hydrophilic glycoside group, for example such as glucose, xylose or arabinose, and
- Embodiment 3 Method according to one of embodiments 1 or 2, characterized in that the polysaccharide is to be chosen from the group comprising xanthan gum, pullulan, sclerotium gum, tara gum, gum of acacia, sodium hyaluronate and mixtures thereof.
- Embodiment 4 Method One of the preceding embodiments, characterized in that the fatty alcohol chosen from the group comprising lauryl alcohol, myristyl alcohol, cetyl alcohol, stearyl alcohol, behenyl alcohol, cetearyl alcohol, preferably cetearyl alcohol, and mixtures thereof.
- the fatty alcohol chosen from the group comprising lauryl alcohol, myristyl alcohol, cetyl alcohol, stearyl alcohol, behenyl alcohol, cetearyl alcohol, preferably cetearyl alcohol, and mixtures thereof.
- Embodiment 5 Method according to any one of the preceding embodiments, characterized in that the alpha hydroxy acid is chosen from the group comprising lactic acid, malic acid, tartaric acid, acid citric acid and mixtures thereof, preferably citric acid.
- the alpha hydroxy acid is chosen from the group comprising lactic acid, malic acid, tartaric acid, acid citric acid and mixtures thereof, preferably citric acid.
- Embodiment 6 Method according to one of the preceding embodiments, characterized in that it contains a dermo-cosmetic active ingredient chosen from the group comprising a natural product, a plant extract, a chemical product, or even a postbiotic, or a combination thereof.
- a dermo-cosmetic active ingredient chosen from the group comprising a natural product, a plant extract, a chemical product, or even a postbiotic, or a combination thereof.
- Embodiment 7 Method according to embodiment 6, characterized in that the dermo-cosmetic active ingredient is a postbiotic and is a bacterial extract originating from a bacterium belonging to the class of proteobacteria, in particular of the class of beta- proteobacteria, in particular a bacterium belonging to the Neisseriaceae subfamily.
- Embodiment 9 Method according to embodiment 6, characterized in that the dermo-cosmetic active ingredient is 4-t-butylcyclohexanol, advantageously combined with pentylene glycol.
- Embodiment 10 Composition as defined in one of embodiments 1 to 9, comprising a dermo-cosmetic active ingredient, for its use for the treatment of an inflammatory skin disorder.
- Embodiment 11 Composition for its use according to the embodiment
- the inflammatory skin disorder is selected from the group comprising dermatitis, pruritus, eczema, psoriasis and rosacea.
- Embodiment 12 Composition for its use according to the embodiment
- the inflammatory skin disorder is rosacea and the dermo-cosmetic active ingredient included in the composition is 4-t-butylcyclohexanol, advantageously combined with pentylene glycol.
- Embodiment 13 Composition as defined in one of embodiments 1 to 9, comprising a dermo-cosmetic active ingredient, for its use for its use for delivering said dermo-cosmetic active ingredient to the skin.
- Embodiment 14 Composition for its use according to embodiment 13, characterized in that the skin has at least one pathological aspect of the inflammatory disorder type, advantageously chosen from the group comprising dermatitis, pruritus, eczema, psoriasis and rosacea.
- the inflammatory disorder type advantageously chosen from the group comprising dermatitis, pruritus, eczema, psoriasis and rosacea.
- Embodiment 15 Composition for its use according to embodiment 14, characterized in that the dermo-cosmetic active ingredient is a postbiotic and is a bacterial extract originating from a bacterium belonging to the class of proteobacteria, in particular of the class beta-proteobacteria, in particular a bacterium belonging to the Neisseriaceae subfamily, more particularly the strain deposited at the CNCM on April 8, 2010 under the reference 1-4290.
- Embodiment 16 Composition for its use according to embodiment 14, characterized in that the dermo-cosmetic active ingredient is 4-t-butylcyclohexanol, advantageously combined with pentylene glycol. DESCRIPTION OF FIGURES
- FIG. 1 shows electron microscopy images of the skin, of a conventional emulsion and of an emulsion according to the invention.
- the emulsion according to the invention has a lamellar structure (multi-lamellar) like that of the skin.
- the classic emulsion has microdroplets.
- FIG. 2A, 2B, 3A, 3B, 4A, 4B, 6A and 6B show the SAXS/WAWS diffraction profiles and patterns, the intensity profiles presented correspond to angular profiles integrated on the meridian (SAXS profile) and the equator profiles (WAXS profiles). WAXS profiles are normalized to facilitate comparison (intensity and position of peaks). The intensity in arbitrary units is expressed as a function of the inverse of the wavelength (A 1 ).
- Figure 2A [Fig. 2A] illustrates diffraction profiles and patterns for composition A (in gray) and for the control (in black).
- Figure 2B [Fig. 2B] is a zoom on the 0.01-0.05 A 1 zone.
- Figure 3A illustrates diffraction profiles and patterns for composition B (in gray) and for the control (in black).
- Figure 3B [Fig. 3B] is a zoom on the 0.01-0.05 A' 1 zone.
- Figure 4A illustrates diffraction profiles and patterns for composition C (in gray) and for control (in black).
- Figure 4B is a zoom on the 0.01-0.05 A' 1 zone.
- FIG. 5 illustrates the results of the factorial correspondence analysis where the points represent the verbal corpora produced at JI, J30, J57 and J85; the triangles represent the distribution of the specific main terms according to the two main dimensions and the boxes group together the specific terms significantly associated with the question according to a T test.
- Example 1 Formulations of compositions according to the invention a) In the form of a cream (Table l) [Table 1] b) As a balm (Table 2) [Table 2]
- Example 2 Effects of different cosmetic compositions on the lipid organization of the stratum corneum by an X-ray diffraction method
- the aim of the study is to characterize the effects on the stratum corneum of 2 cosmetic compositions.
- the technique used to analyze the organization of lipids in the stratum corneum is X-ray diffraction.
- the experiment is carried out in triplicate on an isolated stratum corneum and the measurements are taken one hour after the treatment.
- the outermost layer of the epidermis, the stratum corneum is made up of comeocytes, rich in keratin, surrounded by a lipid matrix. Despite the fact that they represent only 10% of the total mass of the stratum corneum, intercellular lipids play a major role in the barrier function of the skin. For example, the elimination of lipids leads to a loss of water by diffusion.
- the barrier function results from the complex and specific architecture of the inter-comeocyte lipid matrix composed of a mixture of ceramides, cholesterol and long-chain fatty acids. Studies of the ultrastructure of the epidermis using electron microscopy and diffraction techniques have revealed that these lipids are organized into stacked bilayers that are mostly parallel to the skin surface.
- a part of these lipids is covalently bound to comeocytes while another part represents free lipids.
- X-ray diffraction provides information about ordered or partially ordered arrangements of atoms, molecules or macromolecules. X-ray diffraction is a powerful technique to study the organization of lipids and proteins in the skin, and more particularly in the stratum corneum.
- the SAXS signal will provide information on the intercellular stacking of lipids, such as the number of layers.
- the resulting X-ray diffraction pattern shows a series of peaks at approximately 125 ⁇ , 62 ⁇ , 45 ⁇ and 33 ⁇ which inform about the quality of lamellar stacking.
- the WAXS signal gives information on the crystalline organizations of the lipids inside the layers.
- the broadest band comes from the fluid part of the intercellular lipids while the sharp peaks come from the hexagonal or orthorhombic crystal organizations.
- the most intense peak at 4.1 ⁇ is due to both organizations while the peak at 3.7 ⁇ is characteristic of the orthorhombic organization.
- the broad peak at 9.5 ⁇ is produced by keratin intermediate filaments, reflects a change in unit cell size. The more intense and sharp the reflections, the more the lipids are organized. It should be noted that an additional peak may appear, resulting from the interaction of the compositions with the stratum corneum.
- compositions tested are as follows: Composition A: composition of Example IA, Composition B: composition of Example IB, Composition C: composition of the prior art (EP3443949)
- This composition contains: water, glycerin, xanthan gum, tara gum, salicylic acid, methyl propanediol, Aloe vera, inositol, arginine, sorbic acid, squalane, tocopherol, triglycerides (C8-C10), ethyl hexyl glycerin, ethanol, sodium hydroxide, glyceryl laurate, plum oil.
- compositions are applied to the exterior face of the stratum corneum.
- Stratum corneum samples (anatomical site: abdomen) are provided by Novitom.
- the 0.75 x 1.5 cm 2 pieces of stratum corneum were deposited on polymeric supports chosen to be sufficiently adherent to prevent movement of the stratum corneum during the application of the product while allowing detachment without any damage afterwards. the treatment.
- the exterior of the stratum corneum pieces was treated with approximately 5mg/cm 2 of product.
- the application of the product was carried out with a spatula.
- the entire sample of the stratum corneum is thus covered with product.
- About 30 minutes after application of the product the pieces of the stratum corneum are folded on themselves at least four times in order to multiply the quantity of layers of the stratum corneum in the X-ray beam.
- the untreated control samples are also analyzed .
- the diffraction signal from the stratum corneum is integrated over the entire thickness of the superimposed sheets.
- the exposure time per point is 25ms.
- Data processing is performed using ESRF FIT2D software.
- the background pattern (diffraction through air) is subtracted from all sample diffraction patterns.
- the intensity profiles presented correspond to angular profiles integrated on the meridian (S AXS profile) and the equator profiles (WAXS profiles). WAXS profiles are normalized to facilitate comparison (intensity and position of peaks).
- composition A The results obtained with composition A are shown in Figure 2A [Fig. 2A] and Figure 2B [Fig. 2B],
- Figure 2A [Fig. 2A] For the WAXS profile ( Figure 2A [Fig. 2A]), a slight change is observed in the relative intensity of the two peaks characterizing the organization of the lipids. The balance between the crystallized lipids in hexagonal and orthorhombic organization, under the effect of composition A is in favor of the orthorhombic organization. Amorphous lipids are also increased.
- the most intense peak (61 ⁇ ) is shifted to 66 ⁇ . This shift could be interpreted as the addition of an additional peak at 68 ⁇ due to the product, the stratum corneum lipid signal not being modified.
- composition A according to the invention has no effect on lamellar stacking but seems to increase the relative part of crystallized lipids in the orthorhombic organization.
- composition B The results obtained with composition B are shown in Figure 3A [Fig. 3A] and Figure 3B [Fig. 3B], The observations and interpretations are globally similar to those made for composition A. It is interesting to note that the part of crystallized lipids in the orthorhombic organization is even greater after the application of composition B (peak at 3.7 ⁇ more intense). In the SAXS profile, the position of the additional ring is at 65 ⁇ .
- compositions according to the invention increase the organization of the lipid matrix of the stratum corneum, they make it possible to reinforce the lipid barrier.
- composition C composition of the prior art
- Figure 4A composition of the prior art
- Figure 4B Figure 4B
- a significant change is observed, it is the appearance of a new peak (close to that at 3.7 ⁇ on the WAXS profile).
- This new peak is very probably due to the product applied, it could be the incorporation into the stratum corneum of a compound present in composition C but which is not present in the basal state.
- Treatment of the stratum corneum with composition C does not change the ratio of the intensities of the 3.7 ⁇ /4.1 ⁇ WAX peaks. With the SAXS profile, one would assume that the stratum corneum lipid signal does not change.
- composition C does not change the balance between crystallized lipids in hexagonal and orthorhombic organization, but increases the amount of amorphous lipids.
- compositions according to the invention behave differently at the level of the stratum corneum.
- the compositions according to the invention which contain only physio-mimetic compounds, respect the structural organization of the lipids, no compound is in fact incorporated to modify the lipid organization of the stratum corneum; the compositions according to the invention even have the ability to induce a more compact organization of the lipid matrix of the stratum corneum, thus reinforcing the skin barrier.
- Example 3 clinical efficacy of a composition according to the invention
- Study information was provided to each patient prior to the start of the study. This information is accessible, understandable and adapted to each test subject. It was given orally and then in a written document. Each patient gave informed consent.
- the aim of this study is to evaluate in vivo the efficacy and the emotional benefits of a composition according to the invention in the form of a cream (Example 1 A).
- the cream is applied to the face, around the eyes and around the neck, twice a day (morning and evening), every day for 84 days.
- the first application is done under the supervision of a qualified person at the investigation centre.
- the quantity of product applied corresponds to normal conditions of use.
- the sensitivity scale allows a self-assessment of the degree of overall skin irritation. Based on 14 items corresponding to cutaneous irritability, with apparent (5 parameters) and felt (8 parameters) signs, the intensity of each parameter being graduated from 0 to 10. The subject thus completes the questionnaire individually without external influence under operator control. This test is carried out on D1 in control, then 10 to 30 minutes after the first application, still on D1, then on D30, D57 and finally on D85.
- Trans Epidermal Water Loss / TEWL corresponds to the passive diffusion of water through the stratum corneum, from the inside of the body to the outside. Its measurement makes it possible to assess the integrity of the barrier function. When this is altered (case of dry skin for example), the flow of water towards the external environment intensifies, increasing transepidermal water loss.
- a device Vapometer SWL-5 Delfin Technologies, Kuopio, Finland equipped with a probe defining a cylindrical chamber in contact with the skin to measure the water vapor gradient established at the skin surface, was used, the chamber is closed in order to at least partially overcome variations in environmental conditions. Subjects should be in resting conditions for at least 20 minutes prior to measurements. These must be as reproducible as possible, they are carried out by the same operator for the entire study.
- the analysis of the verbatim accounts corresponds to a quantitative or statistical approach to the words contained in the subjects' answers to the two questions asked by the operator during the study (question 1: how have you been feeling these last few days; question 2: what do you think of the quality of your skin?).
- This type of approach is a traditional method in the humanities and social sciences. This evaluation is carried out on D1, then on D30, D57 and on D85. The operator places the subject in front of a mirror, an audio recording is made throughout the evaluation using hidden microphones, the subject not knowing that he is being recorded. The same operator will do all assessments to minimize variability in responses.
- the measurement of the electrodermal reaction is an electrophysiological manifestation, its central determinism makes it a manifestation of the emotional processing of information.
- the electrodermal reaction corresponds to a variation in the electrical resistance of the skin when an electric current passes through it. It is a response that occurs as a result of sensory or emotional stimuli. This variation in electrical resistance of the skin is the result of physiological changes which may be unconscious or imperceptible to the naked eye.
- These neuro-vegetative modifications are the consequences of the activation of the sympathetic nervous system. Indeed, following a psychological stimulation (that is to say emotional), the activity of the sweat glands increases, which leads to a higher conductance of the skin resulting from a very rapid electrodermal reaction. This reaction appears in particular in the palmar and plantar areas.
- the sweat glands are controlled by the sympathetic nervous system through cholinergic ganglion fibers. In this way, the electrodermal response can be used as a physiological sign of emotion.
- start of recording the subject is installed, the operator connects the electrodes for the electrodermal response which are placed on the fingers.
- the subject is blindfolded, a patch inducing a temperature stimulus is placed on the subject's cheek.
- a rest time of 2 minutes is left to stabilize the parameters. It is important that the subject remains still and calm during this rest period.
- the stimuli the operator triggers the patch temperature stimulus for 30 seconds. Then the patch is removed, a rest period of 1 minute is given to the subject, then a sandpaper is applied to the other cheek of the subject for the friction test. At no time (before and after induction of the stimuli) should the patch or sandpaper be visible to the subject.
- the subject applies the product in front of a mirror, then the subject is allowed to rest for 10 to 30 minutes.
- the stimuli the operator again triggers the temperature stimulus and then the friction stimulus as before.
- Results 1/ The results on the self-assessment of skin sensitivity are shown in Tables 4 below. They summarize the means and the standard deviations of the raw values of the 14 parameters (cutaneous irritability, 5 physical signs and 8 functional signs).
- FIG. 5 illustrates the results of the factorial correspondence analysis:
- the dots represent the verbal corpora produced at D1, D30, D57 and D85.
- the triangles represent the distribution of specific main terms according to the two main dimensions.
- the two main dimensions illustrated represent 76.1% of the total variance, which corresponds to an accurate description of the evolution of the verbatim over the course of the study.
- the factorial analysis of the correspondence and the associated specific terms reveal a semantic change, mainly from negative terms on D1 to mainly positive terms on D85.
- the results at D30 and D57 are relatively close and appear intermediate between D1 and D85.
- Example 4 Additional Compositions Formulation of composition according to the invention A - In the form of a cream
- composition tested is composition X: cream composition A above.
- This composition is applied to the outer face of the stratum comeum.
- the SAXS/WAXS diffraction profiles and patterns are shown in Figures 6A and 6B.
- WAX profile on the surface of the SC (gray curve without symbol), the composition shows two broad peaks around 18.5 ⁇ and 4.5 ⁇ (amorphous organization) but these peaks are not observed in the SC.
- the two peaks characterizing the organization of lipids into crystals at 4.1 ⁇ and 3.7 ⁇ (weak) are also observed in the SC.
- composition according to the invention is capable of mimicking the lipid organization and nourishes the SC, in fact the lipids present in the composition penetrate the entire thickness of the SC without affecting its lipid organization.
- FIG. 6 A SAXS (top panel) and 6B WAXS (bottom panel)
- Example 5 Tolerance study of a composition according to the invention
- composition described in example 4 (cream composition B) is tested in this study.
- the main purpose of this study is to test the dermatological and ophthalmic tolerance of the composition according to the invention applied for 21 days and twice a day.
- the secondary objectives are to:
- the study is conducted on 33 subjects aged 27 to 60 (26 women), with a phototype from II to IV. All these subjects present feelings of discomfort in the skin.
- the cream is applied to the face, around the eyes, and to the neck, twice a day (morning and evening), every day for 21 days.
- the first application is done under the supervision of a qualified person at the investigation centre.
- the quantity of product applied corresponds to normal conditions of use.
- the dermatological tolerance of the composition is deemed excellent by the dermatologist, the composition is deemed non-irritant for sensitive skin. Ophthalmic tolerance is also considered excellent by the ophthalmologist.
- composition according to the invention demonstrates a soothing and restorative effectiveness for the skin of subjects with sensitive, hypersensitive, reactive and intolerant skin.
- Effectiveness is demonstrated immediately after the first application. Indeed, a soothing efficacy of the composition according to the invention is demonstrated by the results of the efficacy questionnaire after the first application of the composition. It reduces skin hypersensitivity, reduces feelings of tightness, tingling sensations, itching sensations, heat sensations, discomfort sensations and skin redness. It soothes and comforts the skin. It reduces tightness in 1 minute for the majority of subjects (51.5%) from the first application. It reduces general discomfort within 5 minutes for the majority of subjects (78.8%) from the first application. Finally, it reduces skin redness within 5 minutes for the majority of subjects (66.7%) from the first application.
- the composition according to the invention significantly reduces skin irritability (-55%), tingling (-63%), burning sensation (-63%), heat sensation (-63%), tightness of the skin (-56%), itching (-66%), pain (-73%), general discomfort (-69%), hot flashes (-58 %), redness (-63%), desquamation (-65%), edema (-79%), oozing (-75%), scabs (-87%) and dryness (-59%) ) at D8 compared to D1T0, after 7 days of application, based on the severity of the subjects' skin condition over the past 3 days.
- the soothing efficacy of the composition according to the invention is also demonstrated by the results of the efficacy questionnaire after 7 days of application of the composition. It reduces the hypersensitivity of the skin, reduces feelings of tightness, feelings of tingling, sensations of itching, sensations of heat, sensations of discomfort, skin redness. It soothes and comforts the skin. It reduces tightness within 30 seconds for the majority of subjects (69.7%) over the last 3 days. It reduces general discomfort within 30 seconds for the majority of subjects (69.7%) immediately after application, for the last 3 days. Finally, it reduces skin redness within 30 seconds for the majority of subjects (66.7%) immediately after application, during the last 3 days.
- composition according to the invention significantly reduces the stinging scores by 65%, with 94% of the subjects showing an improvement, demonstrating that the experimental product reduces skin sensitivity and reactivity after 21 days of twice-daily application.
- the composition according to the invention significantly reduces skin irritability (-89%), tingling (-95%), burning sensation (-95%), heat sensation (-92%), skin tightness (-94%), itching (-95%), pain (-96%), general discomfort (-96%), hot flushes (-92%) %), redness (-91%), desquamation (-95%), edema (-97%), oozing (-100%), scabs (-100%) and dryness (-89%) ) at D22 compared to D1T0, after 21 days of application, based on the severity of the subjects' skin condition during the last 3 days.
- the soothing efficacy of the experimental product is also demonstrated by the results of the efficacy questionnaire after 21 days of application of the composition. It reduces tightness within 30 seconds for the majority of subjects (90.9%) immediately after application, during the last 3 days. It reduces general discomfort within 30 seconds for the majority of subjects (90.9%) immediately after application, for the last 3 days. It reduces skin redness within 30 seconds for the majority of subjects (87.8%) immediately after application, within the last 3 days.
- composition according to the invention was very well judged by the subjects, with 97.0% of the subjects satisfied with the composition on D22 (97% liked the product with an average score of 8.24/10 ), and 90.9% of subjects noticed positive changes in the condition of their skin after using the composition for 21 days.
- composition according to the invention calms, controls and reduces the hypersensitivity of the skin with an immediate and lasting effect.
- the majority of results related to skin sensitivity improved from 7 days of application to 21 days of application, showing that the product protects, repairs and durably soothes hypersensitive skin. Skin comfort is restored after using this skin repair composition.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Birds (AREA)
- Chemical & Material Sciences (AREA)
- Emergency Medicine (AREA)
- Dermatology (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Tropical Medicine & Parasitology (AREA)
- Biotechnology (AREA)
- Dispersion Chemistry (AREA)
- Cosmetics (AREA)
Abstract
Description
Claims
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR2009241A FR3114024B1 (fr) | 2020-09-11 | 2020-09-11 | Nouvelle émulsion mimant la peau |
PCT/FR2021/051558 WO2022053770A1 (fr) | 2020-09-11 | 2021-09-13 | Nouvelle émulsion mimant la peau |
Publications (1)
Publication Number | Publication Date |
---|---|
EP4210837A1 true EP4210837A1 (fr) | 2023-07-19 |
Family
ID=74095869
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP21785937.0A Pending EP4210837A1 (fr) | 2020-09-11 | 2021-09-13 | Nouvelle émulsion mimant la peau |
Country Status (3)
Country | Link |
---|---|
EP (1) | EP4210837A1 (fr) |
FR (1) | FR3114024B1 (fr) |
WO (1) | WO2022053770A1 (fr) |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB8327330D0 (en) * | 1983-10-12 | 1983-11-16 | Parsons W J | Membrane analogue emulsions |
DE20321277U1 (de) * | 2003-09-02 | 2006-10-26 | Sebapharma Gmbh & Co. Kg | Kosmetische O/W-Emulsion mit niedrigschmelzender Phytosterolmischung |
US20080171030A1 (en) * | 2005-11-01 | 2008-07-17 | Juice Beauty | Compositions for juice-based moisturizers |
EP2416766B1 (fr) * | 2009-04-09 | 2014-04-09 | Symrise AG | Compositions comprenant du trans-tert-butyl cyclohexanol en tant qu'agent réduisant l'irritation cutanée |
FR2969657B1 (fr) | 2010-12-22 | 2014-02-07 | Fabre Pierre Dermo Cosmetique | Nouvelle bacterie et extraits de ladite bacterie et leur utilisation en dermatologie |
KR20140070430A (ko) * | 2012-11-29 | 2014-06-10 | (주)네오팜 | 피부 외용제 조성물 |
WO2018101930A1 (fr) * | 2016-11-30 | 2018-06-07 | Cgtn C.V. | Composition de soin de la peau présentant des propriétés de protection de la peau et de réparation des lésions cutanées |
US10966914B2 (en) | 2017-06-14 | 2021-04-06 | Counter Brands, Llc | Skin mimicking emulsion |
CN107468621B (zh) * | 2017-09-27 | 2020-04-28 | 杭州梵琳科技有限公司 | 舒敏护肤乳液及其制备方法 |
CN107753379A (zh) * | 2017-12-05 | 2018-03-06 | 佛山微赢电子商务有限公司 | 一种能有效祛痘同时淡化痘痕的祛痘膏及其制备方法 |
CN111297712B (zh) * | 2020-03-13 | 2022-09-06 | 上海新高姿化妆品有限公司 | 一种面霜组合物及其制备方法 |
-
2020
- 2020-09-11 FR FR2009241A patent/FR3114024B1/fr active Active
-
2021
- 2021-09-13 WO PCT/FR2021/051558 patent/WO2022053770A1/fr unknown
- 2021-09-13 EP EP21785937.0A patent/EP4210837A1/fr active Pending
Also Published As
Publication number | Publication date |
---|---|
WO2022053770A1 (fr) | 2022-03-17 |
FR3114024A1 (fr) | 2022-03-18 |
FR3114024B1 (fr) | 2022-09-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP3525889B1 (fr) | Extrait d'anigozanthos flavidus pour son utilisation cosmétique | |
KR101500191B1 (ko) | 피부 케어용 조성물 및 이의 제조 방법 | |
WO2017077497A1 (fr) | Extrait synergique de palmaria palmata et de jasmin, compositions le comprenant et utilisations | |
FR3110414A1 (fr) | Composition cosmétique comprenant au moins une céramide, au moins un micro-organisme tyndallisé et au moins un bisabolol végétal | |
FR3071742A1 (fr) | Procede d'utilisation d'un inhibiteur de let-7b en cosmetique et/ou en nutraceutique | |
EP4210837A1 (fr) | Nouvelle émulsion mimant la peau | |
FR2918882A1 (fr) | Utilisation d'au moins un extrait de parties aeriennes de l'epilobe et/ou de l'onagre pour la preparation d'une composition destinee a restaurer la fonction barriere des tissus keratinises ou des muqueuses | |
CA3189156A1 (fr) | Huile de silybum marianum (l.) gaertn. dans le renforcement de la fonction barriere de la peau | |
WO2022084638A1 (fr) | Huile de paeonia x suffruticosa andrews pour la protection de la peau et des cheveux | |
KR102667625B1 (ko) | 피부장벽 및 피부 보습 개선용 화장료 조성물 및 이의 제조방법 | |
WO2025008278A1 (fr) | Composition pour le traitement de désordres inflammatoires cutanés | |
WO2024134082A1 (fr) | Nouvelles utilisations d'un extrait de phaeodactylum tricornutum | |
WO2024062193A1 (fr) | Utilisations cosmétiques d'un hydrolysat de coproduit d'extraction de la microalgue phaeodactylum tricornutum | |
FR3139466A1 (fr) | Utilisation d’un extrait de poivrier de Sichuan pour un traitement cutané et une composition adaptée à cette utilisation. | |
CN114340613A (zh) | 治疗特应性皮炎的组合物 | |
FR3052666A1 (fr) | Composition cosmetique comprenant un extrait d'amande douce et procede de soin | |
FR3123807A1 (fr) | Serum cosmetique activateur et utilisation dans un procede de soin cosmetique | |
WO2024184164A1 (fr) | Composition alliant une eau thermale et un extrait de lactobacillus acidophilus et son activité de renforcement de la barrière cutanée et contre le vieillissement cutané | |
FR2957259A1 (fr) | Principe actif cosmetique raffermissant issu de piper nigrum, compositions cosmetiques l'incluant et utilisation | |
WO2023186353A1 (fr) | Dextrines hyperbranchees pour leur utilisation topique pour la prevention ou le traitement d'au moins un symptome de l'inflammation cutanee | |
WO2023111440A1 (fr) | Composition et application notamment cosmétique | |
WO2023161293A1 (fr) | Composition cosmétique lipidique destinée à être intégrée dans une composition cosmétique de soin de la peau et des fibres kératiniques | |
WO2023180981A1 (fr) | Extrait de melaleuca alternifolia et ses utilisations cosmétiques | |
FR2962904A1 (fr) | Utilisation de peptides de verbena officinalis pour lutter contre le vieillissement cutane | |
FR3145488A1 (fr) | Utilisation cosmétique d’une association d’extraits de plantes. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: UNKNOWN |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE |
|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |
|
17P | Request for examination filed |
Effective date: 20230327 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
RAP3 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: PIERRE FABRE DERMO-COSMETIQUE |
|
DAV | Request for validation of the european patent (deleted) | ||
DAX | Request for extension of the european patent (deleted) |